An algorithm for guiding clinical judgments about the futility of anti-VEGF treatment of neovascular age-related macular degeneration (nvAMD) has importance from clinical, ethical, and legal perspectives and would be a valuable decision-making tool for retina specialists and payors, according to David T. Wong, MD.
There are a number of ongoing clinical trials investigating treatments for dry age-related macular degeneration (AMD). These modalities include medications that are already in use for other indications and investigational agents representing various novel mechanisms of action.
While participating in an ORBIS Flying Eye Hospital program in Trujillo, Peru, and operating on an elderly patient with a dense cataract under peribulbar anesthesia, James Lehmann, MD, encountered iris prolapse as soon as he made the paracentesis.
Results from the Study Assessing double-masKed Uveitis tREAtrement (SAKURA) program support the efficacy and safety of intravitreal sirolimus 440 mcg (Opsiria, Santen) for treating noninfectious uveitis of the posterior segment, said Pauline T. Merrill, MD.
Recently, evidence has been accumulating to support the theory that cerebrospinal fluid pressure (CSFp) is also important in primary open-angle glaucoma (POAG) and normal-tension glaucoma (NTG), and the relationship has potential implications for clinical practice, said R. Rand Allingham, MD.